MedTrace Logo

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

NCT05550142 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-02-14

No results posted yet for this study

Summary

This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose

50μg/dose

BIOLOGICAL

SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose

100μg/dose

DRUG

Placebo

Saline solution

Sponsors & Collaborators

  • Ningbo Rongan Biological Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Bengbu Medical University

    collaborator OTHER

  • AIM Vaccine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Bengbu Medical University

  • Qiang Wu · The First Affiliated Hospital of Bengbu Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-16
Primary Completion
2022-12-19
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05550142 on ClinicalTrials.gov